Company intelligence / Profile preview

Alfa Wassermann Polska

Warsaw, Mazowieckie, Poland

Ownership: Private
Development stage: Other

Overview

Alfasigma Polska (formerly known as Alfa Wassermann Polska) is the Polish subsidiary of the Italian pharmaceutical group Alfasigma, which was formed through the merger of Alfa Wassermann and Sigma-Tau. The company focuses on marketing and distributing prescription drugs, over-the-counter (OTC) medicines, and dietary supplements in Poland. Its core therapeutic areas include gastroenterology, vascular diseases, orthopedics, rheumatology, and cardiology. Key products in its portfolio include Xifaxan (rifaximin) for gastrointestinal disorders and Dicloreum (diclofenac) for pain and inflammation management.

Therapeutic areas: GastroenterologyCardiovascularNeurologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Alfa Wassermann Polska.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alfa Wassermann Polska.

Explore the full profile